Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ipsogen has announced that it is entering the breast cancer diagnostic market with the European launch of MapQuant Dx Genomic Grade.
Subscribe to our email newsletter
MapQuant Dx Genomic Grade is a molecular diagnostic test to accurately measure tumor grade, a consensus indicator of tumor proliferation, risk of metastasis and response to chemotherapy.
According to the company, MapQuant Dx Genomic Grade test directly measures the expression of the 97 genes that best characterize high-grade versus low-grade tumors. It can resolve these ‘grade 2’ tumors into either ‘grade 1’ or ‘grade 3’ tumors in 80 % of cases.
MapQuant Dx Genomic Grade test is said to be especially useful when tumor grade information can be decisive for prescribing chemotherapy. According to most guidelines, this is the case for hormone-sensitive (ER+) node-negative (N-) invasive breast carcinoma.